• Skip to main content
Scientific Sessions
Scientific Sessions Conference Coverage logo
  • Program
  • #AHA25
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Resources
  • Program
  • #AHA25
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter X icon Facebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Nov 12th, 2020

National Heart Failure Initiative will improve outcomes and quality of life for patients with HF

Initiative supported by founding sponsor Novartis and national sponsor Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC.


2020 11 12 14 11 02

By 2030, more than 8 million people in the U.S. are projected to have heart failure, and deaths from HF are the primary cause of the plateau in age-adjusted death rate from CVD overall. In response,  AHA CEO Nancy Brown has announced the AHA’s National Heart Failure Initiative supported by founding sponsor Novartis and national sponsor Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC.

The initiative will enhance early identification and optimal treatment of HF, along with patient education, to increase healthy time at home and reduce all-cause mortality by 5%. The extensive expertise and infrastructure of the AHA, scientific partners and industry funders will be leveraged to develop concurrent interventions at several points along the patient care spectrum, including clinical and community touch points, specifically:

  • Establish and support learning health care system using quality improvement infrastructure with real-time feedback for identification of key areas for improvement and evaluation of evidence-based approaches.
  • Develop, implement and evaluate scalable patient empowerment and engagement tools that include personalized technology solutions and facilitate improved access to health care.

The initiative will use established AHA approaches of primary data collection, including the Get With The Guidelines® - HF program, to identify, implement and evaluate processes and develop new standards for HF patient management. Both health care and patient interventions will produce large-scale data collection from in-patient, out-patient and community settings resulting in generation of real-world evidence that will be used for characterization and dissemination of best practices.

Interesting Stories
Lp(a) and Peripheral Artery Disease Toolkit
Sponsored by Kaneka Corporation
Lp(a) and Peripheral Artery Disease Toolkit
Unmet Needs in Hypertension Toolkit
Sponsored by Medtronic
Unmet Needs in Hypertension Toolkit
Screening for Kidney Disease to Reduce CVD Risk
Sponsored by Bayer
Screening for Kidney Disease to Reduce CVD Risk
More Content
Getty Images 1410672639
Home
Join #AHA25 in NOLA Nov. 7-10
Sep 19th, 2025
Aha2024 Sm 5277
Home
#AHA25 announces Late-Breaking and Featured Science
Sep 19th, 2025
Aha2024 Sm 0722
Daily Coverage
Don’t miss new Friday, Nov. 7, programming
Sep 19th, 2025
Aha2024 Sm 2850
Daily Coverage
HCMS teams with #AHA25 in new collaboration
Sep 19th, 2025
Aha2024 Sm 2297
Home
Download the #AHA25 mobile app
Sep 19th, 2025
Getty Images 2167930637
Daily Coverage
Book your hotel for #AHA25
Sep 19th, 2025
Getty Images 1645016388
Daily Coverage
Beware of fraudulent website and booking scams
Sep 19th, 2025
241116 Aha Chicago Photo Luke Franke 054
Daily Coverage
Stop by the Simulation Zone at #AHA25
Sep 12th, 2025
Science & Technology Hall
Exhibit Hall
Visit the Science & Technology Hall
Sep 11th, 2025
241116 American Heart Association Keynote 0080
AHA24
Advances in lipid therapeutics
Nov 20th, 2024
Crowd shot
AHA24
New approaches to managing AFib
Nov 20th, 2024
Stage shot
AHA24
Medical therapy for heart failure
Nov 20th, 2024